Cargando…

PROTAC: targeted drug strategy. Principles and limitations

The PROTAC (PROteolysis TArgeting Chimera) technology is a method of targeting intracellular proteins previously considered undruggable. This technology utilizes the ubiquitin—proteasome system in cells to specifically degrade target proteins, thereby offering significant advantages over conventiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koroleva, O. A., Dutikova, Yu. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., Kurkin, A. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762658/ https://www.ncbi.nlm.nih.gov/pubmed/36569659 http://dx.doi.org/10.1007/s11172-022-3659-z

Ejemplares similares

MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
por: Vicente, André T. S., et al.
Publicado: (2022)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
por: Sachkova, Anastasia A., et al.
Publicado: (2022)

The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
por: Poso, Antti
Publicado: (2021)

Recent Advances in PROTACs for Drug Targeted Protein Research
por: Yao, Tingting, et al.
Publicado: (2022)

Editorial: Application of PROTACs as a Novel Strategy for Drug Discovery
por: Ibrahim, Hany S., et al.
Publicado: (2021)

PROTACs: A novel strategy for cancer drug discovery and development
por: Han, Xin, et al.
Publicado: (2023)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
por: Qi, Si-Min, et al.
Publicado: (2021)

Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
por: Yuan, Minghua, et al.
Publicado: (2021)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
por: Arthur, Rachael, et al.
Publicado: (2020)

Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021)

Stress promotes RNA G-quadruplex folding in human cells
por: Kharel, Prakash, et al.
Publicado: (2023)

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
por: Jin, Jinmei, et al.
Publicado: (2020)

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
por: Tamatam, Rekha, et al.
Publicado: (2023)

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
por: Sincere, Nuwayo Ishimwe, et al.
Publicado: (2023)

Designing Soluble PROTACs: Strategies and Preliminary Guidelines
por: García Jiménez, Diego, et al.
Publicado: (2022)

Recent Advances in PROTAC-Based Antiviral Strategies
por: Ahmad, Haleema, et al.
Publicado: (2023)

Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
por: Pei, Haixiang, et al.
Publicado: (2019)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
por: Mancarella, Caterina, et al.
Publicado: (2023)

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
por: Shao, Jingwei, et al.
Publicado: (2021)

Rational Design and Synthesis of HSF1-PROTACs for Anticancer Drug Development
por: Sharma, Chiranjeev, et al.
Publicado: (2022)

Super-Enhancers in the Regulation of Gene Transcription: General Aspects and Antitumor Targets
por: Bruter, A. V., et al.
Publicado: (2021)

An overview of PROTACs: a promising drug discovery paradigm
por: Liu, Zi, et al.
Publicado: (2022)

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
por: An, Sainan, et al.
Publicado: (2018)

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
por: Ishikawa, Minoru, et al.
Publicado: (2020)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

PROTAC targeted protein degraders: the past is prologue
por: Békés, Miklós, et al.
Publicado: (2022)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

Editorial: PROTACs: Targeted therapies for cancer treatment
por: Tabassum, Sobia
Publicado: (2023)

Editorial: PROTACs: Targeted therapies for cancer treatment
por: Tabassum, Sobia
Publicado: (2023)

Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs
por: Muddassir, Mohd., et al.
Publicado: (2020)

Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2)
por: Valdivia, Andres, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_okugbtmkgnppfp4cfblop5tjkc